These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30977980)

  • 1. Absolute Oral Bioavailability of Glasdegib (PF-04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers.
    Shaik N; Hee B; Liang Y; LaBadie RR
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):895-902. PubMed ID: 30977980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers.
    Shaik MN; Hee B; Wei H; LaBadie RR
    Br J Clin Pharmacol; 2018 Jun; 84(6):1346-1353. PubMed ID: 29488303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study.
    Shaik N; Hee B; Wei H; LaBadie RR
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):463-472. PubMed ID: 30536154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers.
    Giri N; Lam LH; LaBadie RR; Krzyzaniak JF; Jiang H; Hee B; Liang Y; Shaik MN
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1249-1260. PubMed ID: 29086063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Model-Based Evaluation of the Effect of Glasdegib on Cardiac Repolarization From a Randomized Thorough QT Study.
    Masters JC; Shaik N; Mendes da Costa L; Hee B; LaBadie RR
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):272-282. PubMed ID: 32790066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies.
    Minami Y; Minami H; Miyamoto T; Yoshimoto G; Kobayashi Y; Munakata W; Onishi Y; Kobayashi M; Ikuta M; Chan G; Woolfson A; Ono C; Shaik MN; Fujii Y; Zheng X; Naoe T
    Cancer Sci; 2017 Aug; 108(8):1628-1633. PubMed ID: 28556364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers.
    Shaik N; LaBadie RR; Hee B; Chan G
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):241-250. PubMed ID: 33388951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism, excretion and pharmacokinetics of [
    Lam JL; Vaz A; Hee B; Liang Y; Yang X; Shaik MN
    Xenobiotica; 2017 Dec; 47(12):1064-1076. PubMed ID: 27866461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers.
    Shaik MN; LaBadie RR; Rudin D; Levin WJ
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):411-8. PubMed ID: 24944041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single-Dose, Matched Case-Control Study.
    Masters JC; LaBadie RR; Salageanu J; Li J; Shaik N
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):707-717. PubMed ID: 33356019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies.
    Ruiz-Garcia A; Shaik N; Lin S; Jamieson C; Heuser M; Chan G
    J Clin Pharmacol; 2021 Mar; 61(3):349-359. PubMed ID: 32974950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure.
    Lin S; Shaik N; Chan G; Cortes JE; Ruiz-Garcia A
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):451-459. PubMed ID: 32885274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.
    Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
    Clin Ther; 2016 Jan; 38(1):53-65. PubMed ID: 26718605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Bioavailability of Metformin Hydrochloride Oral Solution Versus Metformin Hydrochloride Tablets in Fasting Mexican Healthy Volunteers.
    Garza-Ocañas L; González-Canudas J; Tamez-de la O E; Badillo-Castañeda C; Gómez-Meza MV; Romero-Antonio Y; Molina-Pérez A; Amador-Hernández AG
    Adv Ther; 2019 Feb; 36(2):407-415. PubMed ID: 30565181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects.
    Sun H; Ting L; Machineni S; Praestgaard J; Kuemmell A; Stein DS; Sunkara G; Kovacs SJ; Villano S; Tanaka SK
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7431-7435. PubMed ID: 27736760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
    Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study.
    Hsyu PH; Pignataro DS; Matschke K
    Clin Pharmacol Drug Dev; 2018 May; 7(4):373-381. PubMed ID: 29058816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absolute Bioavailability of Esaxerenone and Food Effects on its Pharmacokinetics After a Single Oral Dose in Healthy Japanese Subjects: An Open-Label Crossover Study.
    Kurata A; Furuie H; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
    Adv Ther; 2019 Jul; 36(7):1618-1627. PubMed ID: 31119692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia.
    Norsworthy KJ; By K; Subramaniam S; Zhuang L; Del Valle PL; Przepiorka D; Shen YL; Sheth CM; Liu C; Leong R; Goldberg KB; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Oct; 25(20):6021-6025. PubMed ID: 31064779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.